Research graph
References from Design, Synthesis, and Biological Evaluation of Novel Arylethanone Oxime Ether Derivatives as Potent S1PR1 Agonists for Ulcerative Colitis Therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Ulcerative colitis: signaling pathways, therapeutic targets and interventional strategies
10.1038/s41392-025-02345-1 · 2026 · External reference
Epidemiology and Pathogenesis of Ulcerative Colitis
10.1016/j.gtc.2020.07.005 · 2020 · External reference
Long-term Colectomy Rates of Ulcerative Colitis over 40 Years of Different Therapeutic Eras−Results from a Western Hungarian Population-based Inception Cohort Between 1977 and 2020
10.1093/ecco-jcc/jjac188 · 2023 · External reference
Characteristics of flat-type ulcerative colitis-associated neoplasia on chromoendoscopic imaging with indigo carmine dye spraying
10.1111/den.14628 · 2023 · External reference
Are patients with ulcerative colitis still at increased risk of colon cancer?
10.1016/s0140-6736(19)33225-8 · 2020 · External reference
Ulcerative colitis
10.1016/s0140-6736(23)00966-2 · 2023 · External reference
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
10.3390/jcm11092302 · 2022 · External reference
P0725 The fragility of randomized clinical trials in evaluating novel therapies for Inflammatory Bowel Disease
10.1093/ecco-jcc/jjae190.0899 · 2025 · External reference
Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease
10.1038/ajg.2017.479 · 2018 · External reference
P514 Influence of the frequency of glucocorticosteroid therapy courses on the hormonal resistance in patients with ulcerative colitis
10.1093/ecco-jcc/jjab076.636 · 2021 · External reference
Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators
10.4166/kjg.2024.064 · 2024 · External reference
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
10.1038/ctg.2015.63 · 2016 · External reference
Correction
10.1093/ecco-jcc/jjac104 · 2023 · External reference
Domain-Limited Sub-Nanometer Co Nanoclusters in Defective Nitrogen Doped Carbon Structures for Non-Invasive Drug Monitoring
10.1002/smll.202309264 · 2024 · External reference
Adiposity as a risk factor for inflammatory bowel disease and the mediating effect of metabolic and inflammatory status: A population-based cohort study
10.1002/ueg2.12468 · 2023 · External reference
The inverse association between unhealthy eating habit and mucosal healing among patients with ulcerative colitis
10.1186/s12876-021-01724-6 · 2021 · External reference
Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases
10.1016/j.phrs.2019.02.009 · 2020 · External reference
Sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease and other immune-mediated diseases
10.1007/s00044-022-02961-4 · 2022 · External reference
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
10.1080/14656566.2023.2178898 · 2023 · External reference
Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
10.1016/j.biopha.2022.113341 · 2022 · External reference
S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review
10.1177/17562864221133163 · 2022 · External reference
CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration
10.1126/sciimmunol.aav1263 · 2019 · External reference
S1PR5 is essential for human natural killer cell migration toward sphingosine-1 phosphate
10.1016/j.jaci.2017.11.022 · 2018 · External reference
Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
10.1146/annurev-immunol-020711-075011 · 2012 · External reference
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation
10.1007/s40265-016-0603-2 · 2016 · External reference
Functional roles of sphingolipids in immunity and their implication in disease
10.1038/s12276-023-01018-9 · 2023 · External reference
Sphingosine-1-phosphate and immune regulation: trafficking and beyond
10.1016/j.tips.2010.11.002 · 2011 · External reference
Fingolimod : Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders
10.1146/annurev-pharmtox-010818-021358 · 2019 · External reference
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
10.1016/j.pharmthera.2017.11.001 · 2018 · External reference
Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes
10.1124/jpet.103.062828 · 2004 · External reference
Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects
10.1177/0091270004264165 · 2004 · External reference
Cryptococcal meningoencephalitis in a patient on immunomodulatory drug: A case report
10.1016/j.mycmed.2024.101529 · 2025 · External reference
Pharmacogenetics of siponimod : A systematic review
10.1016/j.biopha.2022.113536 · 2022 · External reference
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
10.1001/jamaneurol.2021.0405 · 2021 · External reference
Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus
10.1371/journal.pone.0193236 · 2018 · External reference
The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis
10.1016/s0140-6736(23)00228-3 · 2023 · External reference
Ozanimod : A Review in Ulcerative Colitis
10.1007/s40265-022-01762-8 · 2022 · External reference
Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3
10.1021/jm0503244 · 2005 · External reference
Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia
10.3389/fimmu.2024.1380975 · 2024 · External reference
Sphingosine-1-Phosphate Signaling in Cardiovascular Diseases
10.3390/biom13050818 · 2023 · External reference
Identifying cardiovascular toxicity associated with sphingosine 1-phosphate receptor modulators: A case-control study based on the FDA adverse event reporting system
10.1016/j.intimp.2025.114520 · 2025 · External reference
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme
10.1093/ecco-jcc/jjae060 · 2024 · External reference
Herpes Simplex Virus (HSV), Varicella-Zoster Virus (VZV), and Cryptococcal Infections Associated With Sphingosine-1-Phosphate Receptor (S1PR) Modulators: A Review (P12-10.005)
10.1212/wnl.0000000000203827 · 2023 · External reference
Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation
10.3390/ijms21207537 · 2020 · External reference
Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5
10.3389/fphar.2022.892097 · 2022 · External reference
A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid
10.1016/0003-2697(90)90113-n · 1990 · External reference
Chapter 3 - cAMP assays in GPCR drug discovery
2017 · External reference
Sex-specific differences in CYP450 isoforms in humans
10.1517/17425255.4.4.413 · 2008 · External reference
Discovery of Novel β-Arrestin Biased Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis
10.1021/acs.jmedchem.5c00859 · 2025 · External reference
Discovery of Novel Selective Dual Agonists Targeting S1PR1 and S1PR5 for the Treatment of Inflammatory Bowel Disease
10.1021/acs.jmedchem.5c02690 · 2026 · External reference
MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes
10.1038/srep02100 · 2013 · External reference
Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor
10.1074/jbc.m610318200 · 2007 · External reference
Cardiac Safety of Ozanimod , a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
10.1002/cpdd.383 · 2018 · External reference
D-Band-Center-Engineered Platinum-Based Nanozyme for Personalized Pharmacovigilance
10.1002/anie.202414625 · 2025 · External reference
Exploration of Tetrahydroisoquinoline- and Benzo[c]azepine-Based Sphingosine 1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis
10.1021/acs.jmedchem.3c00498 · 2023 · External reference
Histological and ultrastructural changes of the colon in dextran sodium sulfate-induced mouse colitis
10.3892/etm.2020.8946 · 2020 · External reference
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
10.1001/jamaneurol.2021.0405 · ExternalCitation · doi-reference
D-Band-Center-Engineered Platinum-Based Nanozyme for Personalized Pharmacovigilance
10.1002/anie.202414625 · ExternalCitation · doi-reference
Cardiac Safety of Ozanimod , a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study
10.1002/cpdd.383 · ExternalCitation · doi-reference
Domain-Limited Sub-Nanometer Co Nanoclusters in Defective Nitrogen Doped Carbon Structures for Non-Invasive Drug Monitoring
10.1002/smll.202309264 · ExternalCitation · doi-reference
Adiposity as a risk factor for inflammatory bowel disease and the mediating effect of metabolic and inflammatory status: A population-based cohort study
10.1002/ueg2.12468 · ExternalCitation · doi-reference
Sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease and other immune-mediated diseases
10.1007/s00044-022-02961-4 · ExternalCitation · doi-reference
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation
10.1007/s40265-016-0603-2 · ExternalCitation · doi-reference
Ozanimod : A Review in Ulcerative Colitis
10.1007/s40265-022-01762-8 · ExternalCitation · doi-reference
A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid
10.1016/0003-2697(90)90113-n · ExternalCitation · doi-reference
Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
10.1016/j.biopha.2022.113341 · ExternalCitation · doi-reference
Pharmacogenetics of siponimod : A systematic review
10.1016/j.biopha.2022.113536 · ExternalCitation · doi-reference
Epidemiology and Pathogenesis of Ulcerative Colitis
10.1016/j.gtc.2020.07.005 · ExternalCitation · doi-reference
Identifying cardiovascular toxicity associated with sphingosine 1-phosphate receptor modulators: A case-control study based on the FDA adverse event reporting system
10.1016/j.intimp.2025.114520 · ExternalCitation · doi-reference
S1PR5 is essential for human natural killer cell migration toward sphingosine-1 phosphate
10.1016/j.jaci.2017.11.022 · ExternalCitation · doi-reference
Cryptococcal meningoencephalitis in a patient on immunomodulatory drug: A case report
10.1016/j.mycmed.2024.101529 · ExternalCitation · doi-reference
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
10.1016/j.pharmthera.2017.11.001 · ExternalCitation · doi-reference
Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases
10.1016/j.phrs.2019.02.009 · ExternalCitation · doi-reference
Sphingosine-1-phosphate and immune regulation: trafficking and beyond
10.1016/j.tips.2010.11.002 · ExternalCitation · doi-reference
Are patients with ulcerative colitis still at increased risk of colon cancer?
10.1016/s0140-6736(19)33225-8 · ExternalCitation · doi-reference
The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis
10.1016/s0140-6736(23)00228-3 · ExternalCitation · doi-reference
Ulcerative colitis
10.1016/s0140-6736(23)00966-2 · ExternalCitation · doi-reference
Exploration of Tetrahydroisoquinoline- and Benzo[c]azepine-Based Sphingosine 1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis
10.1021/acs.jmedchem.3c00498 · ExternalCitation · doi-reference
Discovery of Novel β-Arrestin Biased Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis
10.1021/acs.jmedchem.5c00859 · ExternalCitation · doi-reference
Discovery of Novel Selective Dual Agonists Targeting S1PR1 and S1PR5 for the Treatment of Inflammatory Bowel Disease
10.1021/acs.jmedchem.5c02690 · ExternalCitation · doi-reference
Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3
10.1021/jm0503244 · ExternalCitation · doi-reference
Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease
10.1038/ajg.2017.479 · ExternalCitation · doi-reference
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
10.1038/ctg.2015.63 · ExternalCitation · doi-reference
Functional roles of sphingolipids in immunity and their implication in disease
10.1038/s12276-023-01018-9 · ExternalCitation · doi-reference
Ulcerative colitis: signaling pathways, therapeutic targets and interventional strategies
10.1038/s41392-025-02345-1 · ExternalCitation · doi-reference
MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes
10.1038/srep02100 · ExternalCitation · doi-reference
Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor
10.1074/jbc.m610318200 · ExternalCitation · doi-reference
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
10.1080/14656566.2023.2178898 · ExternalCitation · doi-reference
P514 Influence of the frequency of glucocorticosteroid therapy courses on the hormonal resistance in patients with ulcerative colitis
10.1093/ecco-jcc/jjab076.636 · ExternalCitation · doi-reference
Correction
10.1093/ecco-jcc/jjac104 · ExternalCitation · doi-reference
Long-term Colectomy Rates of Ulcerative Colitis over 40 Years of Different Therapeutic Eras−Results from a Western Hungarian Population-based Inception Cohort Between 1977 and 2020
10.1093/ecco-jcc/jjac188 · ExternalCitation · doi-reference
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme
10.1093/ecco-jcc/jjae060 · ExternalCitation · doi-reference
P0725 The fragility of randomized clinical trials in evaluating novel therapies for Inflammatory Bowel Disease
10.1093/ecco-jcc/jjae190.0899 · ExternalCitation · doi-reference
Characteristics of flat-type ulcerative colitis-associated neoplasia on chromoendoscopic imaging with indigo carmine dye spraying
10.1111/den.14628 · ExternalCitation · doi-reference
Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes
10.1124/jpet.103.062828 · ExternalCitation · doi-reference
CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration
10.1126/sciimmunol.aav1263 · ExternalCitation · doi-reference
Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
10.1146/annurev-immunol-020711-075011 · ExternalCitation · doi-reference
Fingolimod : Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders
10.1146/annurev-pharmtox-010818-021358 · ExternalCitation · doi-reference
Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects
10.1177/0091270004264165 · ExternalCitation · doi-reference
S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review
10.1177/17562864221133163 · ExternalCitation · doi-reference
The inverse association between unhealthy eating habit and mucosal healing among patients with ulcerative colitis
10.1186/s12876-021-01724-6 · ExternalCitation · doi-reference
Herpes Simplex Virus (HSV), Varicella-Zoster Virus (VZV), and Cryptococcal Infections Associated With Sphingosine-1-Phosphate Receptor (S1PR) Modulators: A Review (P12-10.005)
10.1212/wnl.0000000000203827 · ExternalCitation · doi-reference
Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus
10.1371/journal.pone.0193236 · ExternalCitation · doi-reference
Sex-specific differences in CYP450 isoforms in humans
10.1517/17425255.4.4.413 · ExternalCitation · doi-reference
Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia
10.3389/fimmu.2024.1380975 · ExternalCitation · doi-reference
Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5
10.3389/fphar.2022.892097 · ExternalCitation · doi-reference
Sphingosine-1-Phosphate Signaling in Cardiovascular Diseases
10.3390/biom13050818 · ExternalCitation · doi-reference
Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation
10.3390/ijms21207537 · ExternalCitation · doi-reference
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
10.3390/jcm11092302 · ExternalCitation · doi-reference
Histological and ultrastructural changes of the colon in dextran sodium sulfate-induced mouse colitis
10.3892/etm.2020.8946 · ExternalCitation · doi-reference
Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators
10.4166/kjg.2024.064 · ExternalCitation · doi-reference
